Author

Abdul Mannan

Hunter Medical Research InstituteORCID 0000-0001-7680-6594Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Anoop Kumar EnjetiiD· 2 shared Heather C. MurrayiD· 2 shared Matthew D. DuniD· 2 shared Nicole M. VerrillsiD· 2 shared Alicia M. DouglasiD· 1 shared Andrew H. WeiiD· 1 shared Brett NixoniD· 1 shared Brooke M. Harvey· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Anoop Kumar EnjetiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Adaptive resistance to FLT3 inhibitors is potentiated by ROS-driven DNA repair signalling

Dilana Elisabeth Staudt, Zacary P. Germon, Abdul Mannan, Tabitha McLachlan, Heather C. Murray, Ryan J. Duchatel, Bryce C. Thomas, Tyrone S. Beitaki, Holly P. McEwen, Mika L. Persson, Leah Calvert, Izac J. Findlay, Evangeline R. Jackson, Nathan D. Smith, David Anthony Skerrett-Byrne, , Matthew D. Dun

This study identifies ATM-driven DNA repair and ROS addiction as mechanisms of resistance to FLT3 inhibitors in AML and shows ATM inhibition can overcome resistance in vitro and in vivo.

bioRxiv · Jul 26, 2024 · PreprintCancer Biology

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewal.

Danielle R. Bond, Sean M. Burnard, Kumar Uddipto, Kooper V. Hunt, Brooke M. Harvey, Luiza Steffens Reinhardt, Charley Lawlor-O’Neill, Ellise A. Roper, Sam Humphries, Heather C. Murray, Abdul Mannan, Matthew D. Dun, Charles E. de Bock, Nikola A. Bowden, Anoop K. Enjeti, , Heather J. Lee

This study shows that hypomethylating agents induce epigenetic and transcriptional heterogeneity in AML cells, with some cells retaining methylation and showing increased self-renewal, and identifies statins as a potential co-treatment to enhance HMA efficacy.

bioRxiv · Jan 30, 2024Cancer Biology